NCT02859454View on ClinicalTrials.gov

Avelumab for People With Recurrent Respiratory Papillomatosis

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 6, 2016

Primary Completion Date

June 30, 2018

Study Completion Date

September 15, 2021

Conditions
Recurrent Respiratory PapillomatosisJuvenile Laryngeal PapillomaLaryngeal Papilloma, RecurrentRespiratory PapillomatosisHuman Papilloma Virus
Interventions
DRUG

Avelumab

Avelumab 10 mg/kg intravenous (IV) every 2 weeks for up to 6 doses.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02859454 - Avelumab for People With Recurrent Respiratory Papillomatosis | Biotech Hunter | Biotech Hunter